Prospective applications of ultrahigh resolution proteomics in clinical mass spectrometry

ABSTRACT Introduction: Advances in mass spectrometry (MS)-based proteomic strategies have resulted in robust protein biomarker discovery studies often performed on high resolution accurate mass (HRAM) platforms. For successful translation of promising protein biomarkers into useful clinical tests, trans-sector networks and collaboration among stakeholders involved in the biomarker pipeline are urgently needed. Areas covered: In this perspective, literature- and empirical evidence is combined with author’s opinions to discuss the progress of ultrahigh resolution MS and provide insight in its potential for validation and development of clinical tests. Expert commentary: Thus far two ‘low resolution’ MS strategies have been implemented in the clinic: quantification of proteins using triple quadrupole instruments and identification of unknown microorganisms using comparative analysis with spectral libraries on MALDI-TOF instruments. The rise of HRAM technology further boosts the potential of MS-based tests for detection and quantitation of disease-specific biomarkers which meet the analytical performance specifications needed for clinical assays.

[1]  Eric P Skaar,et al.  MALDI FTICR IMS of Intact Proteins: Using Mass Accuracy to Link Protein Images with Proteomics Data , 2015, Journal of The American Society for Mass Spectrometry.

[2]  S. Nicolardi,et al.  Longitudinal monitoring of immunoglobulin A glycosylation during pregnancy by simultaneous MALDI-FTICR-MS analysis of N- and O-glycopeptides , 2016, Scientific Reports.

[3]  A. Marshall,et al.  Petroleomics: Chemistry of the underworld , 2008, Proceedings of the National Academy of Sciences.

[4]  R. Wolfert,et al.  "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. , 2000, Urology.

[5]  Andrew N Hoofnagle,et al.  Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. , 2012, Clinical chemistry.

[6]  A. Van der Laarse,et al.  Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping. , 2016, Clinical chemistry.

[7]  Richard D. Smith,et al.  Proteomics by FTICR mass spectrometry: top down and bottom up. , 2005, Mass spectrometry reviews.

[8]  Silke Machata,et al.  Complete posttranslational modification mapping of pathogenic Neisseria meningitidis pilins requires top‐down mass spectrometry , 2014, Proteomics.

[9]  Ekaterina Mostovenko,et al.  A novel mass spectrometry cluster for high-throughput quantitative proteomics , 2010, Journal of the American Society for Mass Spectrometry.

[10]  P. Lescuyer,et al.  Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold? , 2017, Clinica chimica acta; international journal of clinical chemistry.

[11]  Alexander Scherl,et al.  Clinical protein mass spectrometry. , 2015, Methods.

[12]  M. Thevis,et al.  Mass spectrometry in sports drug testing: Structure characterization and analytical assays. , 2007, Mass spectrometry reviews.

[13]  Holger Moch,et al.  The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report , 2016, PloS one.

[14]  D. Suckau,et al.  Quantification of serum apolipoproteins A-I and B-100 in clinical samples using an automated SISCAPA-MALDI-TOF-MS workflow. , 2015, Methods.

[15]  Laura M. Cole,et al.  Imaging Mass Spectrometry , 2017, Methods in Molecular Biology.

[16]  Sverre Sandberg,et al.  From biomarkers to medical tests: the changing landscape of test evaluation. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[17]  Jeffrey R. Whiteaker,et al.  Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. , 2016, Clinical chemistry.

[18]  J. Loo,et al.  Top‐down protein identification of proteasome proteins with nanoLC‐FT‐ICR‐MS employing data‐independent fragmentation methods , 2014, Proteomics.

[19]  Susan E. Abbatiello,et al.  Targeted Peptide Measurements in Biology and Medicine: Best Practices for Mass Spectrometry-based Assay Development Using a Fit-for-Purpose Approach* , 2014, Molecular & Cellular Proteomics.

[20]  J. Whitelegge.  Intact protein mass spectrometry and top-down proteomics , 2013, Expert review of proteomics.

[21]  Lloyd M. Smith,et al.  Proteoform: a single term describing protein complexity , 2013, Nature Methods.

[22]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[23]  M. Mann,et al.  Precision proteomics: The case for high resolution and high mass accuracy , 2008, Proceedings of the National Academy of Sciences.

[24]  D. Hochstrasser,et al.  Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application , 2013, Clinical chemistry and laboratory medicine.

[25]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[26]  R. Caprioli.  Imaging mass spectrometry: Molecular microscopy for the new age of biology and medicine , 2016, Proteomics.

[27]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[28]  A. Marshall.  Milestones in fourier transform ion cyclotron resonance mass spectrometry technique development , 2000 .

[29]  Matthew J. Rardin,et al.  Multiplexed, Scheduled, High-Resolution Parallel Reaction Monitoring on a Full Scan QqTOF Instrument with Integrated Data-Dependent and Targeted Mass Spectrometric Workflows. , 2015, Analytical chemistry.

[30]  Stefan Enroth,et al.  Identification of genetic variants influencing the human plasma proteome , 2013, Proceedings of the National Academy of Sciences.

[31]  Andrew N Hoofnagle,et al.  The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. , 2009, Journal of immunological methods.

[32]  André M. Deelder,et al.  Ultrahigh resolution profiles lead to more detailed serum peptidome signatures of pancreatic cancer , 2014 .

[33]  Leonard Nyadong,et al.  Laserspray and Matrix-Assisted Ionization Inlet Coupled to High-Field FT-ICR Mass Spectrometry for Peptide and Protein Analysis , 2013, Journal of The American Society for Mass Spectrometry.

[34]  C. Lebrilla,et al.  Absolute quantitation of immunoglobulin G and its glycoforms using multiple reaction monitoring. , 2013, Analytical chemistry.

[35]  M. Mann,et al.  Mass Spectrometry-based Proteomics Using Q Exactive, a High-performance Benchtop Quadrupole Orbitrap Mass Spectrometer* , 2011, Molecular & Cellular Proteomics.

[36]  M. Kostrzewa,et al.  , I . of Nonfermenting Bacteria Gene Sequencing for Species Identification Spectrometry in Comparison to 16 S rRNA Desorption Ionization-Time-of-Flight Mass Evaluation of Matrix-Assisted Laser , 2008 .

[37]  Timothy J. Yeatman,et al.  Proteomic Contributions to Personalized Cancer Care* , 2008, Molecular & Cellular Proteomics.

[38]  Michael J. Sweredoski,et al.  Data-dependent middle-down nano-liquid chromatography-electron capture dissociation-tandem mass spectrometry: an application for the analysis of unfractionated histones. , 2013, Analytical chemistry.

[39]  C. Lebrilla,et al.  Applications of Multiple Reaction Monitoring to Clinical Glycomics , 2015, Chromatographia.

[40]  Arif Ahmed,et al.  Developments in FT-ICR MS instrumentation, ionization techniques, and data interpretation methods for petroleomics. , 2015, Mass spectrometry reviews.

[41]  L. R. Ruhaak,et al.  Protein-Specific Differential Glycosylation of Immunoglobulins in Serum of Ovarian Cancer Patients. , 2016, Journal of proteome research.

[42]  Bruno Domon,et al.  Selectivity of LC-MS/MS analysis: implication for proteomics experiments. , 2013, Journal of proteomics.

[43]  Y. V. D. van der Burgt,et al.  Automation of High-Throughput Mass Spectrometry-Based Plasma N-Glycome Analysis with Linkage-Specific Sialic Acid Esterification. , 2015, Journal of proteome research.

[44]  A. Marshall,et al.  Fourier Transform Ion Cyclotron Resonance Spectroscopy , 1974 .

[45]  Helen Sutton,et al.  Compilation of a MALDI-TOF mass spectral database for the rapid screening and characterisation of bacteria implicated in human infectious diseases. , 2004, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[46]  Philippe Colson,et al.  Modern clinical microbiology: new challenges and solutions , 2013, Nature Reviews Microbiology.

[47]  T. Habuchi,et al.  Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. , 2014, Biochemical and biophysical research communications.

[48]  S. Kingsmore.  Multiplexed protein measurement: technologies and applications of protein and antibody arrays , 2006, Nature Reviews Drug Discovery.

[49]  E. Fung,et al.  A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. , 2010, Clinical chemistry.

[50]  G. Siuzdak.  The emergence of mass spectrometry in biochemical research. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Hoofnagle,et al.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry. , 2013, The Journal of clinical endocrinology and metabolism.

[52]  J. Kellum,et al.  TIMP2•IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients , 2015, The journal of trauma and acute care surgery.

[53]  J. Coon,et al.  Proteomics Moves into the Fast Lane. , 2016, Cell systems.

[54]  C. Lebrilla,et al.  Application of Fourier transform ion cyclotron resonance mass spectrometry to oligosaccharides. , 2005, Mass spectrometry reviews.

[55]  W. Dunne,et al.  Progress in proteomics for clinical microbiology: MALDI-TOF MS for microbial species identification and more , 2015, Expert review of proteomics.

[56]  B. Simons,et al.  Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). , 2011, Analytical chemistry.

[57]  Brian C. Netzel,et al.  Usefulness of a thyroglobulin liquid chromatography-tandem mass spectrometry assay for evaluation of suspected heterophile interference. , 2014, Clinical chemistry.

[58]  Zoltan Takats,et al.  Characterization and identification of clinically relevant microorganisms using rapid evaporative ionization mass spectrometry. , 2014, Analytical chemistry.

[59]  Bruno Domon,et al.  Advances in high-resolution quantitative proteomics: implications for clinical applications , 2015, Expert review of proteomics.

[60]  D. Swinkels,et al.  Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. , 2007, Clinical chemistry.

[61]  B. Domon,et al.  Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.

[62]  Axel Semjonow,et al.  Twenty Years of PSA: From Prostate Antigen to Tumor Marker. , 2007, Reviews in urology.

[63]  N. Anderson,et al.  The Human Plasma Proteome: History, Character, and Diagnostic Prospects , 2003, Molecular & Cellular Proteomics.

[64]  G. Siuzdak,et al.  Innovation: Metabolomics: the apogee of the omics trilogy , 2012, Nature Reviews Molecular Cell Biology.

[65]  B. Meyer,et al.  Glycan analysis of Prostate Specific Antigen (PSA) directly from the intact glycoprotein by HR-ESI/TOF-MS. , 2014, Journal of proteome research.

[66]  Ying Ge,et al.  Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. , 2011, Journal of proteome research.

[67]  Andrew J. Percy,et al.  Clinical translation of MS-based, quantitative plasma proteomics: status, challenges, requirements, and potential , 2016, Expert review of proteomics.

[68]  Brian C. Netzel,et al.  First Steps toward Harmonization of LC-MS/MS Thyroglobulin Assays. , 2016, Clinical chemistry.

[69]  B. Bogdanov,et al.  Developments in FTICR-MS and Its Potential for Body Fluid Signatures , 2015, International journal of molecular sciences.

[70]  M. Plebani,et al.  Clinical utility of the (-2)proPSA and evaluation of the evidence: a systematic review , 2016, Clinical chemistry and laboratory medicine.

[71]  H. V. van Leeuwen,et al.  Typing Pseudomonas aeruginosa Isolates with Ultrahigh Resolution MALDI-FTICR Mass Spectrometry. , 2016, Analytical chemistry.

[72]  Susan E Abbatiello,et al.  Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. , 2010, Clinical chemistry.

[73]  Chad R Weisbrod,et al.  21 Tesla Fourier Transform Ion Cyclotron Resonance Mass Spectrometer: A National Resource for Ultrahigh Resolution Mass Analysis , 2015, Journal of The American Society for Mass Spectrometry.

[74]  Callum G. Fraser,et al.  Biological Variation: From Principles to Practice , 2001 .

[75]  R. Aebersold,et al.  Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.

[76]  Liam A. McDonnell,et al.  Imaging of peptides in the rat brain using MALDI-FTICR mass spectrometry , 2007, Journal of the American Society for Mass Spectrometry.

[77]  Azra Bihorac,et al.  Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury , 2013, Critical Care.

[78]  Makarov,et al.  Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis , 2000, Analytical chemistry.

[79]  Mark P. Molloy,et al.  How specific is my SRM?: The issue of precursor and product ion redundancy , 2009, Proteomics.

[80]  L. R. Ruhaak,et al.  A Method for Comprehensive Glycosite-Mapping and Direct Quantitation of Serum Glycoproteins. , 2015, Journal of proteome research.